Article
AAO makes case for OPT for Medicare patients
Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.
Related Videos
Related Content
Published: October 12th 2024 | Updated: October 11th 2024
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial
